Etofibrate | CAS#31637-97-5 | clofibrate and niacin

MedKoo Cat#: 562324 | Name: Etofibrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Etofibrate is a conjugated clofibrate and niacin. It acts by releasing clofibrate and niacin gradually in the body.

Chemical Structure

Etofibrate

CAS#31637-97-5

Theoretical Analysis

MedKoo Cat#: 562324

Name: Etofibrate

CAS#: 31637-97-5

Chemical Formula: C18H18ClNO5

Exact Mass: 363.0874

Molecular Weight: 363.79

Elemental Analysis: C, 59.43; H, 4.99; Cl, 9.74; N, 3.85; O, 21.99

Price and Availability

Size	Price	Availability
200mg	USD 250.00	2 Weeks
500mg	USD 450.00	2 Weeks
1g	USD 750.00	2 Weeks
2g	USD 1,250.00	2 Weeks
5g	USD 2,750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Etofibrate; Nicotinic Acid; Etofibrato; Etofibratum;

IUPAC/Chemical Name

2-[2-(4-Chlorophenoxy)-2-methylpropanoyl]oxyethyl pyridine-3-carboxylate

InChi Key

XXRVYAFBUDSLJX-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H18ClNO5/c1-18(2,25-15-7-5-14(19)6-8-15)17(22)24-11-10-23-16(21)13-4-3-9-20-12-13/h3-9,12H,10-11H2,1-2H3

SMILES Code

O=C(C1=CC=CN=C1)OCCOC(C(C)(OC2=CC=C(Cl)C=C2)C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 363.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev. 2016 Nov 16;11:CD009753. Review. PubMed PMID: 27849333. 2: Salgado R, Oehmen A, Carvalho G, Noronha JP, Reis MA. Biodegradation of clofibric acid and identification of its metabolites. J Hazard Mater. 2012 Nov 30;241-242:182-9. doi: 10.1016/j.jhazmat.2012.09.029. Epub 2012 Sep 24. PubMed PMID: 23062606. 3: Kublin E, Kaczmarska-Graczyk B, Malanowicz E, Mazurek AP. Methods of chromatographic determination of medicines decreasing the level of cholesterol. Acta Pol Pharm. 2010 Sep-Oct;67(5):455-61. PubMed PMID: 20873411. 4: Emmerich KH, Poritis N, Stelmane I, Klindzane M, Erbler H, Goldsteine J, Görtelmeyer R. [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy]. Klin Monbl Augenheilkd. 2009 Jul;226(7):561-7. doi: 10.1055/s-0028-1109516. Epub 2009 Jul 30. German. PubMed PMID: 19644802. 5: Palumbo B, Oguogho A, Palumbo R, Sinzinger H. Etofibrate enhances 123I-LDL-binding in human liver. Hell J Nucl Med. 2009 Jan-Apr;12(1):13-6. PubMed PMID: 19330175. 6: Korany MA, Hewala II, Abdel-Hay KM. Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques. J AOAC Int. 2008 Sep-Oct;91(5):1051-8. PubMed PMID: 18980118. 7: Reddy PM, Shanker K, Rohini R, Sarangapani M, Ravinder V. Substituted tertiary phosphine Ru(II) organometallics: catalytic utility on the hydrolysis of etofibrate in pharmaceuticals. Spectrochim Acta A Mol Biomol Spectrosc. 2008 Oct;70(5):1231-7. Epub 2007 Nov 17. PubMed PMID: 18160337. 8: el-Gindy A, Hadad GM, Mahmoud WM. High performance liquid chromatographic determination of etofibrate and its hydrolysis products. J Pharm Biomed Anal. 2007 Jan 4;43(1):196-203. Epub 2006 Aug 9. PubMed PMID: 16901673. 9: Geiss HC, Dietlein M, Parhofer KG. Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia. Exp Clin Endocrinol Diabetes. 2003 Sep;111(6):322-4. PubMed PMID: 14520596. 10: Schröder HF. Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors. Water Sci Technol. 2002;46(3):57-64. PubMed PMID: 12227604. 11: Steinmetz A, Fenselau S, Schrezenmeir J. Treatment of dyslipoproteinemia in the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2001;109(4):S548-59. Review. PubMed PMID: 11453042. 12: Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. Braz J Med Biol Res. 2001 Feb;34(2):177-82. PubMed PMID: 11175492. 13: Spósito AC, Maranhão RC, Vinagre CG, Santos RD, Ramires JA. Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease. Atherosclerosis. 2001 Feb 1;154(2):455-61. PubMed PMID: 11166779. 14: Jastrzebska M, Torbus-Lisiecka B, Pieczul-Mróz J, Chelstowski K, Kopciewicz J, Naruszewicz M. Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. Int J Clin Pharmacol Res. 1999;19(1):19-25. PubMed PMID: 10450539. 15: Orth M, Mayer H, Halle M, Luley C. Hemostatic factors in hypertriglyceridemic men: effects of a fatty meal before and after triglyceride-lowering treatment with etofibrate. Thromb Res. 1999 Jun 15;94(6):341-51. PubMed PMID: 10390129. 16: Spósito AC, Caramelli B, Serrano CV Jr, Mansur AP, Ramires JA. Effect of niacin and etofibrate association on subjects with coronary artery disease and serum high-density lipoprotein cholesterol <35 mg/dl. Am J Cardiol. 1999 Jan 1;83(1):98-100, A8. PubMed PMID: 10073791. 17: Sinzinger H. [Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis]. Dtsch Med Wochenschr. 1998 Sep 18;123(38):1116-22. Review. German. PubMed PMID: 9787294. 18: Bocos C, Herrera E. Comparative study on the in vivo and in vitro antilipolytic effects of etofibrate, nicotinic acid and clofibrate in the rat. Environ Toxicol Pharmacol. 1996 Dec 20;2(4):351-7. PubMed PMID: 21781742. 19: dos Santos JE, Loures-Vale AA, Novazzi JP, Rabelo LM, Martinez TL. [Evaluation of efficacy and safety of etofibrate in primary hyperlipidemia. A multicenter study]. Arq Bras Cardiol. 1996 Dec;67(6):419-22. Portuguese. PubMed PMID: 9246832. 20: Fincham JE, Quack G, Wülfroth P, Benadé AJ. Confirmation of efficacy of etofibrate against peripheral atherosclerosis in non-human primates which model human lesion types I-VII. Arzneimittelforschung. 1996 May;46(5):519-25. PubMed PMID: 8737639.